S4366 Down the Gastrointestinal Tract: A Rare Case of Metastatic Esophageal Cancer Spreading to the Colon

Introduction: Esophageal adenocarcinoma (EAC) incidence is rising in high-income countries. The most common sites of metastasis are the liver, lymph nodes, and lungs. Our case demonstrates an exceptionally rare instance of colonic metastasis of EAC. Case Description/Methods: A 64-year-old man with a past medical history of gastroesophageal reflux disease and squamous cell laryngeal cancer in remission was referred for endoscopic evaluation following the detection of adenocarcinoma lesions in the liver on surveillance imaging. He denied any gastrointestinal symptoms. He did not smoke but consumed 10-20 g of alcohol per month. The physical examination was unremarkable. A recent surveillance computed tomography scan showed multiple low attenuated liver lesions and esophageal nodularity. A computed tomography-guided biopsy of the liver lesions revealed poorly differentiated adenocarcinoma that stained positive for cytokeratin-7 (CK7), cytokeratin-20 (CK20), and CDX2, suggesting metastasis from an upper gastrointestinal source. Esophagogastroduodenoscopy revealed multiple fungating masses in the mid and distal esophagus. On colonoscopy, a fungating, infiltrative, and ulcerating large mass was found in the ascending colon. Biopsies from the esophageal and colon masses showed invasive adenocarcinoma. The masses stained positively for CK7, CK20, and CDX2. The colonic mass was also negative for p40 and CK5/6, suggesting that it is a secondary tumor metastasizing from the esophagus. The patient was then started on oxaliplatin, 5-fluorouracil, trastuzumab and pembrolizumab. Discussion: EAC has a high metastatic potential and poor prognosis, and it can be asymptomatic in early stages. Secondary neoplastic lesions in the liver are often found in patients with carcinoma of unknown primary. Esophagogastroduodenoscopy and colonoscopy are reasonable options for the evaluation of carcinoma of unknown primary when the clinical picture or histopathology suggests the possibility of a gastrointestinal source. There are no previously reported cases of EAC resulting in such a large fungating metastatic mass in the colon. Imaging is a crucial part of evaluation of EAC, as it allows staging and identifies candidates for potential curative surgical therapy. It may still fail to detect colonic metastasis like in our patient. Colonoscopy is not routinely recommended in the evaluation of EAC, but our case underscores its utility as part of a multi-disciplinary approach when standard workup fails. The bulky gross morphology of this colonic mass stresses the serious metastatic potential of EAC.

Authors

Publication Details

Journal
The American Journal of Gastroenterology
Published
2025-10-01
DOI
https://doi.org/10.14309/01.ajg.0001144924.69529.b1
Primary Topic
Esophageal Cancer Research and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

S4366 Down the Gastrointestinal Tract: A Rare Case of Metastatic Esophageal Cancer Spreading to the Colon

Baha Aldeen Bani Fawwaz, Tareq Alsaleh, Prachi Mann, Mohammad Maysara Asfari et al.
The American Journal of Gastroenterology
Esophageal Cancer Research and Treatment
article

S4366 Down the Gastrointestinal Tract: A Rare Case of Metastatic Esophageal Cancer Spreading to the Colon

Baha Aldeen Bani Fawwaz, Tareq Alsaleh, Prachi Mann, Mohammad Maysara Asfari, Mohamad Khaled Almujarkesh, Nouman Shafique
article en

Abstract

Introduction: Esophageal adenocarcinoma (EAC) incidence is rising in high-income countries. The most common sites of metastasis are the liver, lymph nodes, and lungs. Our case demonstrates an exceptionally rare instance of colonic metastasis of EAC. Case Description/Methods: A 64-year-old man with a past medical history of gastroesophageal reflux disease and squamous cell laryngeal cancer in remission was referred for endoscopic evaluation following the detection of adenocarcinoma lesions in the liver on surveillance imaging. He denied any gastrointestinal symptoms. He did not smoke but consumed 10-20 g of alcohol per month. The physical examination was unremarkable. A recent surveillance computed tomography scan showed multiple low attenuated liver lesions and esophageal nodularity. A computed tomography-guided biopsy of the liver lesions revealed poorly differentiated adenocarcinoma that stained positive for cytokeratin-7 (CK7), cytokeratin-20 (CK20), and CDX2, suggesting metastasis from an upper gastrointestinal source. Esophagogastroduodenoscopy revealed multiple fungating masses in the mid and distal esophagus. On colonoscopy, a fungating, infiltrative, and ulcerating large mass was found in the ascending colon. Biopsies from the esophageal and colon masses showed invasive adenocarcinoma. The masses stained positively for CK7, CK20, and CDX2. The colonic mass was also negative for p40 and CK5/6, suggesting that it is a secondary tumor metastasizing from the esophagus. The patient was then started on oxaliplatin, 5-fluorouracil, trastuzumab and pembrolizumab. Discussion: EAC has a high metastatic potential and poor prognosis, and it can be asymptomatic in early stages. Secondary neoplastic lesions in the liver are often found in patients with carcinoma of unknown primary. Esophagogastroduodenoscopy and colonoscopy are reasonable options for the evaluation of carcinoma of unknown primary when the clinical picture or histopathology suggests the possibility of a gastrointestinal source. There are no previously reported cases of EAC resulting in such a large fungating metastatic mass in the colon. Imaging is a crucial part of evaluation of EAC, as it allows staging and identifies candidates for potential curative surgical therapy. It may still fail to detect colonic metastasis like in our patient. Colonoscopy is not routinely recommended in the evaluation of EAC, but our case underscores its utility as part of a multi-disciplinary approach when standard workup fails. The bulky gross morphology of this colonic mass stresses the serious metastatic potential of EAC.

The American Journal of GastroenterologyVol. 120(10S2)
Openalex Percentile: Top 41%
Esophageal Cancer Research and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.